Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial

医学 随机对照试验 他汀类 冠状动脉疾病 内科学 临床终点 冠状动脉钙 无症状的 风险因素 阿托伐他汀 队列 心脏病学 物理疗法
作者
P. Venkataraman,Quan Huynh,Stephen J. Nicholls,Tony Stanton,Gerald F. Watts,Thomas H. Marwick
出处
期刊:Atherosclerosis [Elsevier BV]
卷期号:334: 57-65 被引量:14
标识
DOI:10.1016/j.atherosclerosis.2021.08.002
摘要

Coronary artery calcium (CAC) may encourage patients to adhere to primary prevention recommendations. This study sought to evaluate the benefit of a CAC-guided risk-management protocol in those with a family history of premature coronary artery disease (FHCAD).In this Australian multi-centre, randomized controlled trial (Coronary Artery Calcium score: Use to Guide management of Hereditary Coronary Artery Disease, CAUGHT-CAD), asymptomatic, statin-native participants at low-intermediate cardiovascular risk with FHCAD underwent CAC assessment. Those with CAC between 1 and 400 were randomized (1:1) to disclosing the CAC result to both patient and physician and commencing atorvastatin (intervention) or blinding the CAC result with risk factor education only (control). The primary endpoint of this sub-study was change in Pooled Cohort Equation (PCE) at 12 months.Of 1088 participants who were scanned, 450 were randomised and 214 in both groups completed 1-year follow-up. At 1 year, PCE-risk decreased by 1.0% (95% CI 0.13 to 1.81) in the CAC-disclosed group and increased by 0.43% (95%CI 0.11-0.75) in the CAC-blinded group. LDL-C decreased in the CAC-disclosed group in both those who continued (1.5 mmol/L; 95% CI 1.36 to 1.74) and discontinued statins (0.62 mmol/L; 95% CI 0.32 to 0.92) but was unchanged in the CAC-blinded group.Participants unblinded to their CAC showed reductions in LDL irrespective of statin continuation when compared to controls at 12 months. Improvements in individual risk factors and PCE risk were also noted. CAC assessment may positively influence patients and physicians to improve risk factor control.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被LL采纳,获得10
刚刚
搞怪的老九的应助被FOX采纳,获得10
刚刚
快乐尔容完成签到,获得积分10
刚刚
patrickzhao完成签到,获得积分10
2秒前
3秒前
搜集达人的应助被开心的大米采纳,获得10
3秒前
wanci的应助被yc采纳,获得10
5秒前
Lucas的应助被原料药研发粗人采纳,获得10
6秒前
香蕉觅云的应助被芒草lx采纳,获得10
6秒前
7秒前
李梨发布了新的文献求助10
8秒前
希望天下0贩的0的应助被hgy采纳,获得10
8秒前
9秒前
秋刀鱼完成签到 ,获得积分10
11秒前
哈呼呼发布了新的文献求助10
12秒前
Owen的应助被嗨Honey采纳,获得10
12秒前
金月完成签到,获得积分10
12秒前
科研通AI65的应助被原儿采纳,获得10
12秒前
NexusExplorer的应助被胡萝卜卜采纳,获得10
13秒前
xiaoju完成签到,获得积分20
13秒前
xuyangLi完成签到,获得积分10
13秒前
超帅曼柔完成签到,获得积分10
13秒前
14秒前
14秒前
14秒前
ZylaFaye完成签到 ,获得积分10
14秒前
15秒前
uppercrusteve完成签到,获得积分10
15秒前
酷酷的悒发布了新的文献求助10
15秒前
15秒前
16秒前
odd完成签到,获得积分10
16秒前
16秒前
16秒前
风趣的梦琪完成签到,获得积分20
17秒前
星辰大海的应助被快乐土豆采纳,获得10
17秒前
小熊西发布了新的文献求助10
18秒前
Nole的应助被Gcole采纳,获得30
19秒前
Anyixx完成签到,获得积分10
19秒前
健康的孤丝完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193156
求助须知:如何正确求助?哪些是违规求助? 9579416
关于积分的说明 21865319
捐赠科研通 7792722
什么是DOI,文献DOI怎么找? 3437168
关于科研通互助平台的介绍 2560670
邀请新用户注册赠送积分活动 2483977